NCT06871826

Tissue Inhibitor of Metalloproteinases 2 Level in Patients Undergoing Cardiac Surgery

Tissue Inhibitor of Metalloproteinases 2 Level Predicts Acute Kidney Injury in Patients Undergoing Cardiac Surgery

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: Wuhan University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Acute kidney injury (AKI) is one of the most frequent major complications in patients undergoing cardiac surgery. CSA-AKI is independently related to increased perioperative mortality, increased hospital and ICU length of stay as well as heath care expenditure. Identification of relevant biomarkers may lead to early diagnosis and improve patient outcomes and health care costs. The pathophysiology of CSA-AKI is complex and ischemia-reperfusion injury is one of the important factors. Recently, it has been shown that Tissue Inhibitor of Metalloproteinases 2 (TIMP2) is associated with ischemia-reperfusion injury. In this study, relationship between TIMP2 with the risk of CSA-AKI was analyzed and the predictive value of elevated level of TIMP2 for early prediction of CSA-AKI was further evaluated.

Conditions

• Acute Kidney Injury
• Extracorporeal Circulation; Complications
• Surgery

Interventions

Type	Name	Description
DRUG	TIMP2 level	different TIMP2 level after on-pump cardiac surgery

Timeline

• Start date: 2023-07-22
• Primary completion: 2025-01-25
• Completion: 2025-01-25
• First posted: 2025-03-12
• Last updated: 2025-03-12

Locations

1 site across 1 country: China